AGGIORNAMENTO SULLA GESTIONE ATTUALE DELLA TERAPIA DELL’ASMA Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic.

Slides:



Advertisements
Similar presentations
Step-down or Step-off: How do we consider the warning about LABA from the FDA? Robert C. Strunk, MD Strominger Professor of Pediatrics Washington University.
Advertisements

GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
EARLY TREATMENT: USE THE BEST FIRST Early treatment with pharmacological approach Focus on COPD Stage II Pierluigi Paggiaro Cardio-Thoracic and Vascular.
Pediatric Asthma: Navigating Through Guidelines and Black Boxes Vinit K. Mahesh, M.D.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
GOLD Clasification Antonio Anzueto MD Professor Medicine University of Texas.
Global Initiative for Asthma (GINA) Teaching slide set 2015 update
DIFFICULT TO TREAT ASTHMA By PROF. RAMADAN M. NAFAE PROFESSOR AND HEAD OF CHEST DEPARTMENT FACULTY OF MEDICINE ZAGAZIG UNIVERSITY.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Impact of Montelukast on Symptoms of Mild-to-Moderate Persistent Asthma and Exercise-Induced Asthma: The ASTHMA Survey The ASTHMA* survey was supported.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Pharmaceutical Care in Asthma Omotola Morakinyo
Classification and guideline treatment
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
AHEAD COSMOS and COMPASS Studies. The AHEAD Study.
Strategies for asthma management VARIABLE ! Prof Huib Kerstjens Groningen Research Institute for Asthma and COPD University Medical Center Groningen.
Allergic vs. Non-Allergic Asthma
Component 4 Medications.
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.
An Update in Pediatric Asthma DR.NUFOUD AL- SHAMMARI CONSULTANT PEDIATRIC PULMONOLOGIST CHAIRPERSON OF MUBARK AL-KABEER HOSPITAL KUWAIT.
© Global Initiative for Asthma GINA Global Strategy for Asthma Management and Prevention 2015 This slide set is restricted for academic and educational.
Wendy Pigg Practice support Pharmacist/Independent Prescriber
Overview of Changes to the NAEP Asthma Guidelines Breathe California’s Clinical Asthma Collaborative Susan M. Pollart, MD, MS University of Virginia Family.
Pharmacologic Treatment Of Asthma 1 د. ميريانا البيضة.
Respiratory medication use in Australia 2003–2013: Treatment of asthma and COPD AIHW: Correll PK, Poulos LM, Ampon R, Reddel HK and Marks GB. Published.
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Linda Rogers and Joan Reibman Curr Opin Pulm Med. (2012) January Vol. 18 Stepping down asthma treatment: how and when Journal club R4. Yoo,
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Dr Mazen Qusaibaty MD, DIS / Head Pulmonary and Internist Department Ibnalnafisse Hospital Ministry of Syrian health – Dr Mazen.
1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.
What doctors should do to support patients with uncontrolled and severe asthma. Jaime Correia de Sousa Ioanna Tsiligianni Anders Østrem.
GOLD 2017 major revision: Summary of key changes
UPDATE SULLA TERAPIA DELL’ASMA
The Advanced Role of Tiotropium in
Pharmacology of Anti- Asthmatic Medications
Curriculum Vitae Nama : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM
Global Initiative for Asthma (GINA) Teaching slide set 2017 update
Research where it is most needed National Respiratory Strategy
Asthma: In my practice Bangladesh Dr GM Monsur Habib.
Asthma Yardstick Annals of Allergy, Asthma & Immunology
Monitoring asthma in primary care
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:
The Role of Anticholinergic Therapy in Moderate to Severe Asthma
The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control  Barbara P. Yawn, MD, MSc  Mayo Clinic Proceedings 
Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.
Volume 153, Issue 4, Pages (April 2018)
When Would You Use Single Inhaler Triple Therapy in COPD?
Severe Asthma in Primary Care: Identification and Management
The Modern Management of Asthma: Getting it right Part 2
12 months before treatment 12 months after treatment
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Roflumilast negli studi di Fase III: i dati di efficacia
Gestione clinica della BPCO
Pinja Ilmarinen, PhD, Leena E
The efficacy and safety of omalizumab in pediatric allergic asthma
Global Initiative for Asthma (GINA) What’s new in GINA 2019?
Global Initiative for Asthma (GINA) What’s new in GINA 2019?
Global Initiative for Asthma (GINA) What’s new in GINA 2019?
Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation  Anthony P. Sampson, PhDa, Emilio Pizzichini, MD, PhDb,
The paradoxes of asthma management: time for a new approach?
Roflumilast in aggiunta ai corticosteroidi inalatori
Where Does Anticholinergic Therapy Fit in Moderate to Severe Asthma?
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.
Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.
Presentation transcript:

AGGIORNAMENTO SULLA GESTIONE ATTUALE DELLA TERAPIA DELL’ASMA Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department, University of Pisa Università degli Studi di Pisa Azienda Ospedaliera Pisana PneumoTrieste 2016 Trieste aprile 2016

ERJ, 2015

Bronchial Asthma heterogeneity in clinical presentation Large difference in clinical manifestations, related to: – Severity of the disease – Heterogeneity of inducers and/or triggers – Level of adherence to therapeutic plan Existance of different phenotypes – Clinical and functional – Biological Difference in: – Strategy of asthma treatment – Strategy in asthma management

A new definition of asthma (GINA 2014): a heterogeneous disease GINA 2014, draft

Bronchial Asthma heterogeneity in clinical presentation Large difference in clinical manifestations, related to: – Severity of the disease – Heterogeneity of inducers and/or triggers – Level of adherence to therapeutic plan Existance of different phenotypes – Clinical and functional – Biological Difference in: – Strategy of asthma treatment – Strategy in asthma management

Asthma phenotypes Eosinophilic vs non-eosinophilic asthma Eosinophilic phenotype – Allergen-induced asthma, children asthma – Severe asthma with frequent exacerbations (CS- dependent asthma) Non eosinophilic phenotype – Specific “triggers” (pollutants, endotoxins, chemicals, viruses) – In all asthma severity levels – Stable over time ? – Lower response to ICS  different therapeutic strategies ?

Fahy, Nat Rev Immunol 2015

Both eosinophilic and non-eosinophilic inflammatory patterns in asthma seem fairly stable over time Bacci et al, Respirology Sputum Eosinophils 87% 5% Sputum Eosinophils Dente et al, IAAI 2015

Assessment of asthma severity GINA 2014

Asthma treatment: open points Mild asthma: – Regular low-dose ICS vs «as-needed» therapy – Low-dose ICS vs LRTA Moderate asthma: – Regular low-medium dose ICS/LABA vs SMART therapy Severe asthma: – Anticholinergics drugs – Omalizumab: efficacy and safety – New biologics

0 0,5 1 1,5 2 As needed combination As needed albuterol Regular beclomethasone Regular combination Number of exacerbations per patients/year EFFECT OF EXACERBATIONS Papi et al, N Engl J Med 2007;356;

prn BDP/S prn S regular BDP regular BDP/S ** ** mg CUMULATIVE DOSE OF BECLOMETHASONE (BDP) Papi et al, N Engl J Med 2007;356;

Randomised controlled trial if inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma Beasly R et al, ERJ February 2016 The Novel START trial will investigate the efficacy and safety of ICS/fast-onset LABA as sole reliever therapy in pts with intermittent or mild persistent asthma. Primary aim: compare efficacy *BUD/FORM with: SABA reliever therapy SABA reliever therapy Maintenance ICS plus SABA Maintenance ICS plus SABA *N° of exacerbations per patient x year

New aspects of asthma management Confirming the importance of maintenance therapy – Except mild asthma – Major role of combination therapy (LABA/ICS) – Major focus on step-up and step-down Using different strategy for assessing and maintaining the control – Monitoring symptoms, PEF and/or inflammation Focus on severe asthma – Add tiotropium (triple therapy) – Add omalizumab – Add new biologics

Regular treatment with ICS or combinations is the recommended treatment in almost all treatments steps GINA 2014

ICS/LABA combination therapy Different ICS/LABA combinations Fluticasone propionate/salmeterol MDI and DPI – Different strenght, standard dosing Budesonide/formoterol DPI – Single strenght, different dosing BDP/formoterol MDI and DPI – Single strenght, different dosing Fluticasone propionate/formoterol MDI – Different strenght, standard dosing Fluticasone furoate/vilanterol DPI – Different strenght, once daily Different indications – Traditional treatment vs maintenance and reliever treatment – Different severity ?

FP/F combination: comparison with monocomponents Latorre et al, Pulm Pharm Ther 2015

Efficacy and tolerability of FF/VI 184/22 (high strenght) in asthma: drop out for lack of efficacy Durante le 24 settimane di trattamento un numero inferiore di pazienti trattati con FF/VI è uscito dallo studio (3%) rispetto a quanto successo nei bracci trattati con FF (11%) e FP (9%) O’Byrne et al; Eur Respir J. 2014

Role of combination therapy GINA 2014

“Maintenance and reliever” strategy reduces asthma exacerbations, as well as or better than traditional strategies Humbert et al, Allergy 2008

New aspects of asthma management Confirming the importance of maintenance therapy – Except mild asthma – Major role of combination therapy (LABA/ICS) – Major focus on step-up and step-down Using different strategy for assessing and maintaining the control – Monitoring symptoms, PEF and/or inflammation Focus on severe asthma – Add tiotropium (triple therapy) – Add omalizumab – Add new biologics

Green et al, Lancet 2002 The control of sputum eosinophilia is associated with a reduction in asthma exacerbations, but only for eosinophilic exacerbations Jayaram et al, ERJ 2006

Biomarker-based or symptom-based adjustement of ICS is not superior to physician-based adjustment Calhoun et al, JAMA 2013

New aspects of asthma management Confirming the importance of maintenance therapy – Except mild asthma – Major role of combination therapy (LABA/ICS) – Major focus on step-up and step-down Using different strategy for assessing and maintaining the control – Monitoring symptoms, PEF and/or inflammation Focus on severe asthma – Add tiotropium (triple therapy) – Add omalizumab – Add new biologics

Severe asthma: heterogeneity of mechanisms Chung et al, ERJ 2014

Anticholinergics in asthma Short-acting anticholinergics in asthma – Less effective than short-acting beta2-agonists – Recommended only in acute severe asthma attack Tiotropium: – Largely used in COPD Recent studies on tiotropium in asthma – Since 2007 Large RCTs with Tiotropium in Asthma (TinA) – In severe asthmatics (Primo-TinA: Kernstjen, NEJM 2012) – In moderate asthmatics (Mezzo-TinA: Kernstjen, LancetResp 2015) – In mild asthmatics (Grazia-TinA: Paggiaro, JACI 2015 under revision)

First two coprimary endopoints (FEV1) Kerstjens et al, NEJM 2012

Severe exacerbation rate -- 21% -Time to first ex: + 56 days -NNT: 15 Minor changes in symptoms - ACQ in trial 1 (n.s.) in trial 2 (p=0.06) - AQLQ in trial 1 (n.s.) in trial 2 (p=0.02) Kerstjens et al, NEJM 2012 Third coprimary endopoint (severe exacerbations)

GINA 2015 – changes to Steps 4 and 5 © Global Initiative for Asthma GINA 2015, Box 3-5, Steps 4 and 5 *For children 6-11 years, theophylline is not recommended, and preferred Step 3 is medium dose ICS **For patients prescribed BDP/formoterol or BUD/formoterol maintenance and reliever therapy # Tiotropium by soft-mist inhaler is indicated as add-on treatment for patients with a history of exacerbations; it is not indicated in children <18 years. Other controller options RELIEVER STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 Low dose ICS Consider low dose ICS Leukotriene receptor antagonists (LTRA) Low dose theophylline* Med/high dose ICS Low dose ICS+LTRA (or + theoph*) As-needed short-acting beta 2 -agonist (SABA) Low dose ICS/LABA* Med/high ICS/LABA Refer for add-on treatment e.g. anti-IgE PREFERRED CONTROLLER CHOICE Add tiotropium# High dose ICS + LTRA (or + theoph*) Add tiotropium# Add low dose OCS As-needed SABA or low dose ICS/formoterol**

Triple therapy in asthma Combination of ICS, LABA, LAMA – Different inhalers – Single inhaler (once daily vs twice daily) Current position (EMA approved) – LAMA in addition to ICS/LABA – Severe uncontrolled asthma with exacerbations Future perspectives – ICS + LAMA vs ICS + LABA – Advantages: safety vs efficacy vs asthma heterogeneity

Tiotropium is effective when added to ICS in moderate asthma Kerstjen et al, Lancet Respiratory 2015

Novelli et al, Pulm Pharm Ther 2014

Different targets for intervention on the «inflammatory cascade» Pelaia et al, Med Inflamm 2015

Future biologic drugs in asthma NameTargetPhaseBiomarkers MepolizumabIL-5Phase III – EMA+Blood eos BenralizumabIL-5 RPhase IIIBlood eos ReslizumabIL-5Phae IIIBlood eos LebrikizumabIL-13Phase IIIPeriostin TralokinumabIL-13Phase II-IIIDPP-4, periostin (?) DupilumabIL-4Phase III?? BrodalumabIL-17Phase II??

New initiatives on severe asthma in Italy PROXIMA - an observational, 2 phase, patient reported outcomes study – Level of asthma control – Impact on physical and emotional status SANI – severe asthma network in Italy – GINA Italy, SIAIC, SIMeR

Main evolution in asthma guideline: «Asthma as a heterogeneous disease» Identification of different phenotypes – According to etiology – According to pathogenesis – According to severity Implication for treatment («target therapy») – With current drugs – With biologic drugs – With allergen-immunotherapy – With thermoplasty «tailoring» asthma approach

Asthma: from population-level to patient-level «personalized therapy» GINA 2014